Cisplatin - NEVER in cats

Cisplatin is a platinum-based chemotherapy agent that was historically one of the first platinum compounds used in veterinary oncology for treating cancers in dogs. As the original platinum chemotherapy drug, cisplatin demonstrated significant antitumor activity but also carries serious toxicity concerns that have led to its partial replacement by carboplatin in many veterinary applications. The drug remains effective against various solid tumors in dogs but requires careful patient selection and intensive supportive care during administration. Most critically, cisplatin is absolutely contraindicated in cats, where it causes fatal pulmonary toxicity, and this species restriction must be strictly observed.

The mechanism of action of cisplatin involves formation of cross-links within DNA molecules, disrupting the genetic template that cancer cells require for replication. The platinum atom central to the molecule binds to DNA bases, creating bonds between adjacent nucleotides or between the two strands of the double helix. These intrastrand and interstrand cross-links interfere with DNA replication and transcription, ultimately triggering cell death pathways. Rapidly dividing cancer cells are particularly vulnerable because they have less time to repair DNA damage before attempting cell division. This mechanism provides broad activity against various tumor types.

Cisplatin administration in dogs requires extensive supportive care protocols to minimize the serious nephrotoxicity associated with this drug. The standard administration protocol involves prolonged intravenous fluid diuresis before, during, and after cisplatin infusion to protect the kidneys from drug-induced damage. This intensive fluid therapy requirement typically necessitates hospitalization for six to eight hours or longer on treatment days. The drug is administered by trained veterinary oncology professionals in settings equipped to provide appropriate supportive care. Treatment intervals of three to four weeks allow adequate recovery between doses.

The safety profile of cisplatin in dogs presents greater challenges than its relative carboplatin, with nephrotoxicity representing the primary dose-limiting concern. Even with aggressive fluid diuresis protocols, kidney damage remains a risk that requires careful monitoring. Severe nausea and vomiting are common and require aggressive antiemetic therapy. Bone marrow suppression also occurs. These toxicity concerns have led many veterinary oncologists to prefer carboplatin for indications where both drugs show efficacy. However, cisplatin remains valuable in specific situations and continues to be used by oncology specialists in appropriate patients. The absolute contraindication in cats cannot be overemphasized, as administration to cats results in fatal acute pulmonary edema.

Osteosarcoma treatment in dogs represents an important application for cisplatin chemotherapy, particularly in the adjuvant setting following limb amputation. Osteosarcoma is an aggressive bone cancer affecting primarily large and giant breed dogs, with microscopic metastatic disease presumed present in nearly all cases at diagnosis. Adjuvant chemotherapy following amputation targets these micrometastases to extend survival time. While carboplatin has become more commonly used for this indication due to its improved tolerability, cisplatin remains an effective option and some studies have suggested potentially superior survival benefits in certain patient populations. The choice between platinum agents depends on individual patient factors and oncologist preference.

Transitional cell carcinoma of the bladder and other urothelial malignancies have historically been treated with cisplatin in dogs, though combination protocols involving piroxicam and mitoxantrone have become more popular for this specific cancer type. Cisplatin demonstrates activity against these tumors through its DNA cross-linking mechanism. The drug may be considered when other treatment approaches have been unsuccessful or are contraindicated. However, the kidney toxicity concerns with cisplatin require particular caution in patients with bladder cancer, where urinary tract obstruction could compound renal risks.

Various carcinomas may respond to cisplatin-based treatment protocols. Squamous cell carcinoma, which can occur in various locations including the oral cavity, skin, and digits, may be treated with cisplatin when surgical removal is incomplete or not feasible. Nasal tumors, including carcinomas and other malignancies, may be addressed with cisplatin as part of multimodal treatment approaches. Thyroid carcinomas and other epithelial tumors are potential candidates for platinum-based chemotherapy. The drug's broad activity against carcinomas reflects its mechanism targeting DNA replication in rapidly dividing cells.

Intralesional cisplatin therapy represents a specialized application using the drug locally rather than systemically. Cisplatin can be formulated in a collagen matrix, sesame oil, or other vehicles for direct injection into accessible tumors. This approach delivers high local drug concentrations while minimizing systemic exposure and associated toxicities. Intralesional cisplatin has been used for cutaneous tumors, sarcomas, and other accessible masses. This delivery method avoids the intensive fluid diuresis requirements of systemic administration while providing local tumor control.

The selection of cisplatin over alternative chemotherapy agents requires careful consideration of multiple factors. The drug's toxicity profile, including nephrotoxicity, severe nausea, and the requirement for prolonged hospitalization during administration, must be weighed against potential benefits. Patient factors including pre-existing kidney function, overall health status, and ability to tolerate intensive treatment influence drug selection. For most indications, carboplatin offers similar efficacy with improved tolerability, making it the preferred platinum agent. However, specific situations may favor cisplatin based on individual patient characteristics or prior treatment history.

Cisplatin dosing in dogs requires careful calculation based on body surface area, following standard oncology dosing principles. The veterinary oncologist determines the appropriate dose considering established protocols and individual patient factors, particularly kidney function status. Accurate patient weight is essential, and assessment of renal function through blood work helps guide dosing decisions. The dose may be modified based on kidney values, prior treatment tolerance, or other patient-specific considerations. Only veterinary oncology specialists with appropriate training and facilities should administer cisplatin.

The administration protocol for cisplatin requires extensive intravenous fluid diuresis to protect the kidneys from drug-induced damage. The standard protocol involves several hours of pre-treatment hydration with intravenous crystalloid fluids to establish brisk urine production before cisplatin administration. The chemotherapy drug is then given as a slow intravenous infusion while fluid administration continues. Post-treatment diuresis continues for several additional hours to maintain kidney perfusion and drug clearance. This intensive protocol typically requires six to eight hours of hospitalization or longer, representing a significant commitment of time and resources.

Treatment protocols typically involve administration every three to four weeks, allowing adequate time for recovery from side effects and bone marrow regeneration between doses. For osteosarcoma, four to six treatments represent a commonly recommended course following amputation, though protocols vary. The total number of treatments and overall treatment duration depend on the cancer type, treatment goals, and individual patient tolerance. Blood work is performed before each treatment to assess kidney function and bone marrow status. Treatment delays or dose modifications may be necessary if recovery between treatments is inadequate.

Antiemetic therapy is a critical component of cisplatin administration protocols due to the severe nausea and vomiting this drug commonly causes. Pre-treatment with antiemetic medications helps prevent or reduce gastrointestinal side effects. Multiple antiemetics may be used in combination for optimal effect. Ongoing antiemetic support for one to three days following treatment addresses delayed nausea. This aggressive supportive care has dramatically improved tolerability compared to early experiences with cisplatin when antiemetic options were more limited.

Missed appointments require prompt communication with the veterinary oncology team. Given the specialized nature of cisplatin administration and the preparation required, rescheduling is typically necessary rather than simply dropping in for treatment. The appropriate timing for rescheduling depends on how much time has elapsed and the specific clinical situation. Maintaining treatment schedules as closely as possible optimizes outcomes while accommodating necessary adjustments.

Completing recommended treatment protocols provides the best opportunity for controlling microscopic disease and extending survival. However, the significant toxicity potential with cisplatin means that treatment decisions are made collaboratively, weighing expected benefits against side effects experienced. Some patients may not tolerate the full planned treatment course, requiring early discontinuation or switch to alternative agents. Individual patient assessment guides all treatment decisions.

Nephrotoxicity represents the most serious and dose-limiting side effect of cisplatin in dogs, distinguishing this drug from the related agent carboplatin. Cisplatin damages the renal tubular cells, which can lead to acute or chronic kidney injury. Even with aggressive intravenous fluid diuresis protocols, some degree of kidney damage may occur, particularly with repeated treatments. Pre-existing kidney disease increases vulnerability to cisplatin-induced nephrotoxicity. Monitoring kidney values before each treatment and periodically during therapy helps detect developing renal damage, allowing intervention or treatment modification before severe injury occurs.

Severe nausea and vomiting are hallmark side effects of cisplatin that require proactive management with aggressive antiemetic therapy. Without appropriate supportive care, the gastrointestinal effects can be debilitating and significantly impact quality of life. Modern antiemetic protocols have dramatically improved tolerability, but nausea and appetite reduction may still occur despite treatment. Both acute effects occurring during or shortly after treatment and delayed effects over the following days can occur. Maintaining adequate nutrition and hydration during treatment is important for patient wellbeing and treatment tolerance.

Bone marrow suppression occurs with cisplatin therapy, leading to decreased production of white blood cells, red blood cells, and platelets. The nadir for blood cell counts typically occurs around two weeks after treatment, with recovery before the next scheduled dose in most patients. During periods of low white blood cell counts, dogs are at increased risk of infection. Signs of infection, including fever, lethargy, or any symptoms of illness, require prompt veterinary evaluation. Regular blood work monitoring tracks bone marrow function and guides treatment decisions.

Ototoxicity, or damage to hearing, has been documented with cisplatin use in various species and may occur in dogs, though it is difficult to assess clinically. The inner ear structures can be affected by platinum compounds, potentially leading to hearing impairment. While this effect is not routinely monitored in veterinary patients, awareness of this potential issue is appropriate. Neurological effects including peripheral neuropathy can also occur, potentially manifesting as changes in gait or coordination.

Local tissue effects from extravasation are less severe with cisplatin compared to vesicant drugs like vincristine, but infiltration outside the vein is still undesirable and should be avoided through proper intravenous technique. Other potential effects include mild liver enzyme elevations and general malaise following treatment. The cumulative nature of some toxicities means that tolerance may decrease with repeated treatments, potentially limiting the total number of doses that can be safely administered.

The absolute contraindication of cisplatin in cats cannot be overstated, as administration to feline patients results in fatal acute pulmonary edema that is not preventable with supportive care. This species-specific toxicity is unique to cats and does not occur in dogs when appropriate protocols are followed. Any multi-pet household with cats receiving veterinary cancer treatment must ensure that cisplatin is never mistakenly administered to the feline patient. The devastating and uniformly fatal outcome of cisplatin administration in cats makes this contraindication absolute with no exceptions. Veterinary professionals must verify species identification before cisplatin administration.

Pre-existing kidney disease represents a significant contraindication or at minimum requires extreme caution when considering cisplatin therapy in dogs. The drug's nephrotoxic potential means that patients with compromised renal function are at high risk of serious kidney damage. Dogs with elevated kidney values on pre-treatment blood work may not be appropriate candidates for cisplatin. Mild renal compromise might be manageable with dose reduction and enhanced monitoring, but moderate to severe kidney disease typically precludes cisplatin use. Carboplatin offers an alternative with less nephrotoxic potential for patients with kidney concerns.

Known hypersensitivity to cisplatin or other platinum compounds contraindicates treatment. Dogs that have experienced severe allergic reactions to carboplatin should not receive cisplatin due to expected cross-reactivity. Any history of unusual reactions to platinum-based chemotherapy should be disclosed to the oncology team. Alternative chemotherapy agents from different drug classes would be selected for patients with platinum hypersensitivity.

Severe bone marrow suppression or active serious infection should be addressed before cisplatin administration. The drug's myelosuppressive effects compound pre-existing bone marrow dysfunction. Active infections require treatment before chemotherapy-induced immunosuppression is added. Blood work verification before each treatment ensures adequate bone marrow recovery from previous treatments.

Pregnancy and nursing are contraindications due to potential fetal harm and possible drug excretion in milk. Severely debilitated patients may not tolerate the intensive treatment protocol required for cisplatin administration. Dehydration must be corrected before treatment proceeds, as adequate hydration is essential for the renal-protective fluid diuresis protocol. Comprehensive patient evaluation identifies all factors that might contraindicate cisplatin therapy.

Complete disclosure of all medications, supplements, and treatments the patient is receiving is essential before cisplatin therapy. Drug interactions can significantly affect both safety and efficacy of treatment. Given cisplatin's nephrotoxic potential, interactions affecting kidney function are of particular concern. The veterinary oncology team requires comprehensive medication information to identify potential interactions and adjust treatment plans accordingly. This includes prescription drugs, over-the-counter products, supplements, and any alternative therapies.

Nephrotoxic drug interactions are critically important for cisplatin therapy. Concurrent use of other medications that can affect kidney function significantly increases the risk of serious renal damage. Aminoglycoside antibiotics, certain nonsteroidal anti-inflammatory drugs, amphotericin B, and other nephrotoxic agents should be avoided or used with extreme caution in patients receiving cisplatin. The oncology team evaluates all concurrent medications for potential renal effects. Drug changes or treatment timing adjustments may be necessary to minimize combined kidney stress. Even seemingly routine medications should be reviewed for potential nephrotoxic effects.

Other chemotherapy agents may be used in combination with cisplatin for specific protocols, requiring careful attention to overlapping toxicities. Myelosuppressive combinations increase neutropenia risk and may necessitate modified dosing or extended intervals. Drugs metabolized by or affecting kidney function require particular scrutiny when combined with cisplatin. Veterinary oncologists experienced in chemotherapy protocol design can manage these combinations appropriately.

Drugs affecting the antiemetic regimen used alongside cisplatin can impact treatment tolerability. Adequate nausea control is essential for patient comfort and ability to maintain nutrition during treatment. Interactions that reduce antiemetic effectiveness could worsen the gastrointestinal side effects of cisplatin. The complete medication list allows the oncology team to select compatible antiemetic agents.

Supplements and herbal products should be disclosed and discussed with the oncology team. Some products may have effects on kidney function, drug metabolism, or other relevant processes. The safety of many supplements in combination with chemotherapy is not established. Pet owners should consult the veterinary team before using any supplements during treatment. This comprehensive approach to medication management helps ensure the safest possible treatment experience.

The critical warning regarding cisplatin use in cats must be prominently emphasized: this drug is absolutely fatal in cats and must never be administered to feline patients under any circumstances. Cisplatin causes acute pulmonary edema in cats that results in death and is not preventable with any supportive care measures. This toxicity is unique to the feline species and does not respond to the fluid diuresis protocols that protect dogs. Multi-species veterinary facilities must have rigorous safeguards to prevent accidental feline administration. This warning cannot be overemphasized given the uniformly fatal outcome.

Renal function monitoring is paramount for all dogs receiving cisplatin. Pre-treatment kidney values must be assessed, and treatment should only proceed when kidney function is adequate. Serial monitoring during the treatment course helps detect developing nephrotoxicity, allowing early intervention or treatment modification. Adequate hydration before, during, and after treatment is essential for kidney protection. The extensive fluid diuresis protocol is not optional but rather a requirement for safe cisplatin administration. Any deviation from established protocols significantly increases nephrotoxicity risk.

Chemotherapy handling and administration precautions protect both patients and veterinary personnel. Cisplatin should only be administered by trained professionals in appropriate settings with proper safety equipment. Personal protective equipment, including gloves and gowns, protects staff from drug exposure. Proper preparation techniques, administration procedures, and waste disposal protocols must be followed. These precautions ensure consistent, safe treatment delivery.

Environmental precautions following treatment address drug excretion in patient waste. Cisplatin and its metabolites are excreted in urine, feces, and other body fluids for a period following treatment. Pet owners should wear gloves when handling waste and wash hands thoroughly after any contact. Pregnant women and immunocompromised individuals should avoid contact with the patient's waste products. The veterinary team provides specific guidance on precautionary measures and their duration.

Special populations requiring additional consideration include geriatric patients with potential age-related kidney function decline, patients with concurrent diseases, and dogs receiving other potentially nephrotoxic treatments. Pre-existing cardiovascular disease may affect tolerance of the large fluid volumes required during administration. Individual patient assessment guides appropriate precautions and determines whether cisplatin or an alternative agent is most appropriate.

Cisplatin storage is managed by the veterinary facility, as this chemotherapy agent is administered only in specialized clinical settings with appropriate supportive care capabilities. The drug requires specific storage conditions according to manufacturer specifications, typically including protection from light and controlled temperature. Proper storage maintains drug stability and ensures effectiveness through the labeled expiration date. Veterinary facilities maintain appropriate storage for chemotherapy agents separate from other medications, with inventory management systems tracking expiration dates.

Formulation-specific handling requirements reflect the hazardous nature of cisplatin and all chemotherapy agents. Drug preparation must occur in biological safety cabinets or using appropriate containment systems to protect personnel from exposure. Aseptic technique is maintained throughout preparation. Proper dilution in appropriate intravenous fluids is required for administration. Once prepared, the drug has specific stability requirements that dictate storage conditions and time to use. The prepared solution must be protected from light during administration. Visual inspection confirms the solution is appropriate for use before administration begins.

Safe handling and disposal procedures protect personnel, patients, and the environment from chemotherapy exposure. All materials contacting cisplatin must be disposed of as hazardous pharmaceutical waste following applicable regulations. This includes gloves, gowns, preparation supplies, administration sets, and any items contacting patient excreta during the elimination period. Spill response procedures must be established with staff trained in their implementation. Documentation of chemotherapy handling and disposal is maintained as required. Pet owners receive instructions on managing their pet's waste during the excretion period, including wearing gloves and proper waste containment.

Breed considerations for cisplatin relate primarily to the epidemiology of cancers most commonly treated with this drug, particularly osteosarcoma in large and giant breed dogs. Certain breeds have dramatically elevated osteosarcoma risk compared to the general canine population. Rottweilers, Great Danes, Irish Wolfhounds, Scottish Deerhounds, Saint Bernards, Doberman Pinschers, and Greyhounds are among breeds most commonly affected by this cancer. These breeds therefore represent a significant portion of dogs receiving platinum-based chemotherapy. Pet owners of high-risk breeds benefit from awareness of osteosarcoma warning signs, including lameness and bone swelling.

The MDR1 gene mutation common in herding breeds does not significantly affect cisplatin handling, as this drug is not a major substrate for the P-glycoprotein transporter affected by this mutation. Collies, Australian Shepherds, Shetland Sheepdogs, and other affected breeds can receive cisplatin without the specific dose modifications required for drugs like vincristine. However, when cisplatin is part of a multimodal protocol including other drugs, MDR1 status may remain relevant for those other agents. Comprehensive treatment planning considers all aspects of patient genetics and concurrent medications.

Size-related considerations are relevant for cisplatin therapy because the large and giant breeds most commonly receiving this drug for osteosarcoma present specific challenges. Accurate weight measurement is essential for proper dosing. The large fluid volumes required for the diuresis protocol scale with patient size, requiring appropriate intravenous fluid supplies and monitoring. Drug costs and hospitalization requirements may be substantial for very large patients. Very small dogs are less commonly treated with cisplatin, as the cancers most responsive to this drug occur less frequently in small breeds, and carboplatin offers a more manageable alternative when platinum therapy is needed.

Age-related factors influence treatment tolerance. Osteosarcoma typically affects middle-aged to older large breed dogs, meaning many patients may have some age-related changes in organ function. Kidney function assessment is particularly important, as age-related renal decline may increase vulnerability to cisplatin's nephrotoxic effects. Cardiovascular status affects tolerance of the large fluid volumes required during treatment. Individual patient assessment determines whether cisplatin or an alternative agent is most appropriate for each patient's specific circumstances.

Carboplatin is the most closely related medication to cisplatin, as both are platinum-based chemotherapy agents with similar mechanisms of action. Carboplatin was specifically developed to provide platinum compound efficacy with reduced toxicity compared to cisplatin. In dogs, carboplatin has largely replaced cisplatin for many indications due to its significantly improved safety profile, particularly the absence of the severe nephrotoxicity that characterizes cisplatin. Carboplatin does not require the extensive fluid diuresis protocol needed for cisplatin, making administration more practical. For osteosarcoma and other indications where both drugs show activity, carboplatin is often preferred, though some oncologists believe cisplatin may offer superior efficacy in certain situations.

Other chemotherapy drug classes used for cancers that might be treated with cisplatin include doxorubicin for osteosarcoma, mitoxantrone and piroxicam combinations for transitional cell carcinoma, and various agents for other carcinomas. The selection of specific agents depends on tumor type, patient factors, prior treatment history, and individual oncologist experience. Multimodal approaches combining chemotherapy with surgery and radiation therapy are common for many cancers. Targeted therapies including tyrosine kinase inhibitors offer different mechanisms of action for certain tumor types.

Supportive care medications are essential components of cisplatin treatment protocols. Aggressive antiemetic therapy using multiple agents including maropitant, ondansetron, and others helps manage the severe nausea associated with cisplatin. Appetite stimulants may be prescribed if food intake decreases. The intravenous fluids used for the diuresis protocol are critical supportive medications that enable safe drug administration. Pain management is important for patients with painful cancers like osteosarcoma. Antibiotics may be needed if infection develops during periods of immunosuppression. The veterinary oncology team coordinates all supportive medications to optimize patient comfort and treatment tolerance.